Sionna Therapeutics

SIONPhase 2

Sionna Therapeutics is advancing a pipeline of next-generation cystic fibrosis correctors designed to fully restore CFTR function in patients with the prevalent F508del mutation. The company's lead program, SION-638, is in Phase 1 clinical trials, with a portfolio of follow-on candidates targeting distinct mechanisms. Sionna's strategy is to develop combination therapies that could offer superior clinical benefit compared to current standards of care, addressing a significant unmet need in the CF patient population.

Market Cap

$1.6B

Employees

11-50

Focus

Biotech

SION · Stock Price

USD 36.39+11.39 (+45.56%)

Historical price data

AI Company Overview

Technology Platform

Structure-based drug design platform targeting the NBD1 domain of the CFTR protein to develop small-molecule correctors for cystic fibrosis.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
SION-719 + Placebo-to-match SION-719	Cystic Fibrosis (CF)	Phase 2
SION-451 + SION-2222 + SION-109 + Placebo SION-451 + Placebo SION-2222 + Placebo...	Cystic Fibrosis (CF)	Phase 1

Funding History

Total raised: $293M

Series B$182MOrbiMedJan 15, 2023

Series A$111MOrbiMedOct 15, 2021

Opportunities

The primary growth opportunity is to demonstrate best-in-class efficacy for F508del CF patients, capturing a segment of the multi-billion dollar CF market.

Success could also position Sionna as an attractive partner or acquisition target for larger pharmaceutical companies seeking to enhance their respiratory disease portfolios.

Risk Factors

Key risks include clinical trial failure of the lead candidate, intense competition from the established market leader (Vertex Pharmaceuticals), and the challenges of commercializing a therapy in a complex rare disease market dominated by a single player.

Competitive Landscape

Vertex Pharmaceuticals is the dominant competitor with a complete portfolio of approved CFTR modulators. Sionna's differentiation lies in its novel NBD1-targeting mechanism, which aims to provide additive or superior efficacy when combined with existing therapies, addressing residual unmet need.

Publications

Pipeline